Myocardial recovery after hypoxia may be determined not only by the extent of metabolic depression during the hypoxic period but also by changes in cation contents as well. Calcium overload during reoxygenation, mediated in part by Na-Ca exchange and supported by the rise in cell sodium during hypoxia, may be one factor. The effects of amiloride (0.1 mM), a diuretic that inhibits Na+-H+ and Na-Ca exchanges in cardiac sarcolemma and mitochondria preparations, were studied during hypoxia-reoxygenation in the isovolumic, isolated rat heart. During hypoxia, cell sodium, measured using potassium ethylenediamine tetraacetate cobaltate as an extracellular marker, increased in amiloride and amiloride-free hearts, but there was no increase in cell calcium (3.3±0.3 vs. 3.6±0.9 ,umolUg dry wt; p=NS). Amiloride did not alter developed pressure (DP), end-diastolic pressure (EDP), pH, or integrated areas of adenosine triphosphate (ATP) and phosphocreatine (PCr) (determined by phosphorus-31-nuclear magnetic resonance spectroscopy) during hypoxia or normal perfusion conditions. Forty minutes after reoxygenation, however, cell calcium was significantly lower in the amiloride (5.1±1.3 ,imoUg dry wt) than in the amiloride-free group (10.4± 1.8 ,umolVg dry wt;p<0.001), and there was improved recovery of DP (percent of initial) (72±12% vs. 41l12%;p<0.001), PCr (99+9%o vs. 70+14%;p<0.001), and pH (7.17±0.17 vs. 6.88±0.16; p<0.001) in the amiloride group. To determine whether this dose of amiloride inhibits the manifestations of sodium-mediated calcium gain in the same model during normoxia, the metabolic and functional sequelae of lithium-substituted low sodium (50 mM) perfusion were studied. Amiloride significantly limited the manifestations of sodium-meditated calcium gain as indexed (all expressed as percent of control) by a lower peak DP (221±25% vs. 284±20%o) at 3 minutes, improved preservation of PCr (85+10%o vs. 68±9%o) and ATP (104±12% vs. 84±9%o), lower rise in inorganic phosphate (201+74% vs. 332±106%), and a smaller fall in intracellular pH (7.01±0.04 vs. 6.70±i0.15, p<0.05) for all metabolic parameters during a 20-minute period. These findings indicate that at a dose shown to alter the manifestations of sodium-mediated calcium gain in the isolated rat heart, amiloride limits cellular calcium gain during reoxygenation after hypoxia and significantly improves mechanical and metabolic recovery, even though it does not alter the decline in metabolic parameters during hypoxia.
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One important route of calcium influx is Na-Ca exchange, the direction and magnitude of which is determined by the transsarcolemmal sodium and calcium gradients and the transmembrane potential.7,8 A decrease in perfusate or extracellular sodium or an increase in cytosolic sodium is believed to result in increased cellular calcium via this mechanism.9-15 During hypoxia, cell sodium rises. 16, 17 Despite this rise, cell calcium does not initially increase,1718 probably because of the associated acidosis and lack of high-energy phosphates-both of which would be expected to limit Na-Ca exchange and mitochondrial calcium uptake.19-23 These conditions are rapidly reversed during reoxygenation, however, and a relatively high cytosolic sodium could then support calcium influx. If this sequence of events were operative during reoxygenation, inhibition of sodium-supported calcium gain would be expected to decrease cell calcium overload and improve functional and metabolic recovery. Amiloride (3,5-diamino-6-chloro-N-[diaminomethylene] pyrazine-carboxamide monohydrochloride) decreases cell sodium and inhibits Na+-H+ and Na-Ca exchanges in cardiac sarcolemmal vesicles and other preparations.24-33 For these reasons, the effects of amiloride on the metabolic, ionic, and functional sequelae of exposure to hypoxia and reoxygenation in the isolated, intact rat heart preparation were evaluated. Additional studies were performed during lithium-substituted low sodium perfusion to determine whether amiloride inhibits the metabolic and functional consequences of sodium-mediated calcium gain in the isolated, intact heart during normoxic perfusion conditions.
Methods

Heart Preparation
Retired, male breeder Wistar rats (500-650 g) were given heparin (1,000 units i.p.) and anesthetized with 50-100 mg i.p. sodium pentobarbital. After rapid excision of the hearts, the aortae were cannulated for retrograde perfusion with oxygenated solution at 340 C (pH 7.4) at a constant flow of 12 ml/min with a Masterflex 7562-10 peristaltic pump (Cole-Parmer, Barrington, Illinois). The use of constantflow perfusion was critical for these studies of hypoxia-reoxygenation and low sodium perfusion with cellular ionic concentration determination by extracellular markers, although such perfusion may be associated with high coronary perfusion pressures during hypoxic periods. The perfusate contained (mM) Na 144, K 5, Ca 1.5, HEPES 6, magnesium 0.9, chloride 152, and glucose 15; lidocaine 5 gug/ml was added for control of ventricular arrhythmias. Hearts that were later assayed for ionic contents were perfused with 1 mM KCoEDTA, which was used as an extracellular marker, and potassium chloride was reduced to 4 mM. Atrioventricular conduction block, obtained by surgical incision into the interatrial septum via the atrial appendages, was readily assessed by visual inspection of heart rate reduced from more than 250 to 60-80 beats/min. Each heart was then paced at a rate of 85 beats/min with a Grass SD-9 stimulator (South Natick, Massachusetts) via a potas-sium chloride wick electrode placed into the right ventricle and secured to the pulmonary artery outflow. A latex balloon attached to PE 190 tubing was inserted into the left ventricle through the mitral valve and filled with aqueous solution to obtain the maximum developed systolic pressure. Throughout the experiment, the balloon volume was not altered; thus, the heart functioned isovolumically. The other end of the PE 190 tubing was connected to a Statham P23Db transducer (Gould Instrument, Cleveland, Ohio) wired to a Gould-Brush direct-writing recorder for continuous measurements of left ventricular pressure.
Phosphorus-31-Nuclear Magnetic Resonance Spectroscopy
The perfused hearts were positioned in a 25-mm probe of a Bruker WH 180 superconducting magnet (field strength, 4.2 T) (Bruker Instruments, Billerica, Massachusetts) interfaced with a Nicolet 1280 computer (Nicolet Instrument, Madison, Wisconsin). Pulsed, Fourier-transformed, minimally saturated spectra were obtained with a 2-second interpulse delay between 650 pulses of 28-,usec duration. This pulse rate allows enhanced signal to noise over fully relaxed spectra but results in some phosphocreatine (PCr) saturation with PCr 75-+9%, ATP 97+15%, and inorganic phosphate (Pi) 93 +30% of values from fully relaxed spectra determined under identical conditions in four additional hearts. Data were accumulated during 5-minute acquisitions (152 pulses) with a 4-K table and 3,000-Hz spectral width and sequentially summed to obtain total 10-minute data sets, the results of which are presented at the midpoint in time of each acquisition. Proton decoupling was not used.
Changes in tissue contents of Pi, PCr, and ATP were determined by integrating areas under individual peaks with baselines determined by hand, without knowledge of the presence or absence of amiloride, using a Hewlett-Packard 9810 digitizer (Palo Alto, California). [34] [35] [36] Previous studies indicate that changes in Pi, PCr, and ATP assessed by such nuclear magnetic resonance (NMR) techniques correlate well with direct biochemical quantification. [36] [37] [38] The aqueous solution within the latex balloon contained trimetaphosphate as a standard. Intracellular pH was measured from the chemical shift of the Pi peak relative to the PCr peak.39
Cell Ionic Quantification
KCoEDTA (1 mM) was used as an extracellular marker9,40 and synthesized in pure crystalline form by the method of Dwyer et al. 41 Wet weights of pieces of left ventricular myocardium were obtained immediately after the experiment, and dry weights were obtained after at least 48 hours at 1100 C. All tissues were handled with and stored in Teflon instruments and containers. The dried tissue was digested with nitric and perchloric acids, and the total tissue calcium, cobalt, and sodium were determined by flame atomic absorption spectrophotometry. The extracel-lular space (ECS) was calculated by the following formula:
where Cot is the total tissue cobalt content, Cop is the perfusate cobalt concentration, and H20 is total tissue water (ml) obtained from the dry weight assuming 1 ml H20=1 g.
The intracellular ionic concentration was calculated by subtracting the extracellular ionic content from the total content:
where C, is the cellular ion content, Ct is the total tissue ion content, and Cp is the perfusate concentration of the ion. The intracellular ionic contents are expressed as micromoles per gram dry weight.
Protocols
All hearts underwent an initial stabilization period during perfusion with oxygenated solution. Baseline data were subsequently collected during a 20-minute period. To ensure uniformity, hearts with a developed pressure (DP) of less than 100 mm Hg or that could not be paced were excluded from the study protocol. In the first series of experiments, contractile and metabolic data were obtained during 60 minutes of perfusion with solution containing no amiloride (n=6), 0.1 mM amiloride (n=5), or 1.0 mM amiloride (n=5). In one set of hearts, the pH effect of amiloride was measured in the presence of 2.0 mM 2-deoxyglucose. The 0.1 mM amiloride concentration had no effect on contractile function or metabolism and was used in subsequent studies.
In the hypoxia-reoxygenation experiments, hearts were perfused during baseline, hypoxia, and reoxygenation periods with (n=9) or without (n=9) 0.1 mM amiloride. Perfusate during the hypoxic period was bubbled with 100% N2, and glucose was omitted. Functional and metabolic recovery plateaued after 40 minutes of reoxygenation in preliminary experiments. The protocol was terminated at the end of hypoxia in additional amiloride (n =5) and amiloride-free (n =4) hearts to assess the ionic effects of hypoxia per se and of amiloride on these effects.
Amiloride effects during hypoxia-reoxygenation may in part be attributable to blockade of sodiummediated calcium gain. Therefore, additional experiments were conducted in separate hearts to assess whether amiloride was capable of decreasing the metabolic and contractile manifestations of increased cellular calcium that accompany normoxic low sodium perfusion in the perfused rat heart. 15, 35, 36 In these experiments, hearts were perfused for 20 minutes with oxygenated solution in which 90 mM Na was replaced with 90 mM Li in the presence (n =5) and absence (n=5) of 0.1 mM amiloride. 
Statistics
All results are expressed as mean±SD. The data are compared using unpaired t tests or repeatedmeasures analysis of variance (ANOVA).42 Results 
Time-Control Studies and Concentration Effects ofAmiloride in the Absence of Hypoxia and Reoxygenation
The mean DP, PCr, and ATP (as percent of baseline); end-diastolic pressure (EDP; mm Hg); and pH during a 60-minute period of perfusion with amiloride-free (n=6), 0.1 mM amiloride (n=5), and 1.0 mM amiloride (n=5) solution are depicted in Figure 1 and summarized in Table 1 . There is no significant change in these contractile and metabolic parameters during normal perfusion without amiloride (Table 1) . Thus, this preparation is functionally and metabolically stable over 1 hour. DP in hearts exposed to amiloride 1.0 mM decreased to a mean of 67±9% of baseline level after 60 minutes of exposure (p<0.001). EDP, however, was not changed. The decreased DP is associated with a with 31P-NMR spectroscopy when only a small Pi peak is present, the same experiment was performed in another group of hearts (n=4) that had been briefly pretreated with 2.0 mM 2-deoxyglucose. This allows measurement of pH from the chemical shift of the 2-deoxyglucose-6-phosphate peak.43,44 A similar fall in pH with exposure to 1.0 mM amiloride also was measured with this technique. Exposure to 0.1 mM amiloride caused an early, small, transient increase in DP, which peaked at 10-15 minutes and then returned to and remained near baseline levels.
There was no effect of 0.1 mM amiloride on EDP or any of the metabolic parameters including pH, which was also assessed using 2.0 mM 2-deoxyglucose. Therefore, this amiloride dose, 0.1 mM, was used in the subsequent experiments.
Hypoxia and Reoxygenation Experiments
In the next series of experiments, the effects of amiloride 0.1 mM during 40 minutes of hypoxia followed by 40 minutes of reoxygenation were studied. Baseline DP (138±+18 vs. 144±18 mm Hg; p=NS), EDP (17+4 vs. 15+5 mm Hg;p=NS), intracellular pH (7.23 +0.06 vs. 7.21+0.06; p=NS), and metabolism as indexed by PCr-to-Pi ratios (5.94+2.9 vs. 5.91-+ 1.8; p=NS) do not differ in the amiloride and amiloridefree hearts, respectively. 31P-NMR spectra from representative hearts in the two groups are shown in Figures  2A and 2B . Hypoxia causes a rapid decrease in PCr, an increase and acidic shift in Pi, and a gradual decrease in ATP, all of which are similar in the presence and absence of amiloride. There is more complete recovery of PCr, Pi, and pH during reoxygenation in the amiloride-treated heart.
The effects of amiloride on contractile function and metabolism during hypoxia and reoxygenation in all hearts are presented in Figures 3 and 4 . Mean DP ( Figure 3A) declined rapidly during the first 15 minutes of hypoxia and then fell more slowly during the next 25 minutes to 8+5% and 7+3% of baseline values in the amiloride-free and amiloride hearts, respectively. Amiloride does not affect the rate and extent of this decline. Mean EDP ( Figure 3B ) rises minimally during the first 15 minutes and then more dramatically during the last 25 minutes of hypoxia to 110±+12 and 114±+15 mm Hg in the amiloride-free and amiloride hearts, respectively. PCr and ATP ( Figures 4A and 4B ) fall during hypoxia, the former more rapidly. However, amiloride has no effect on the decline of either. Intracellular pH ( Figure 4C ) declines modestly in each group during the hypoxic insult, falling from 7.21+0.06 and 7.23+0.03 under baseline conditions to 7.03+0.06 and 7.06+0.15 at the end of hypoxia in the amiloride-free and amiloride hearts, respectively. Therefore, under these experimental conditions, 0.1 mM amiloride has no functional or metabolic effects before or during hypoxia.
In contrast to the lack of significant effects during hypoxia, amiloride significantly improves the recovery of contractile ( Figure 3 ) and metabolic (Figure 4 ) parameters during reoxygenation. DP ( Figure 3A Initial developed pressure (144+18 and 138±18 mm Hg) and enddiastolic pressure (15±5 and 17±4 mm Hg) do not differ between amiloride-free and amiloride hearts, respectively (p=NS). Despite the lack of an amiloride effect during normoxia or hypoxia, developed pressure is higher and enddiastolic pressure is lower during reoxygenation in the amiloride-exposed hearts.
returns to 72+ 12% of the baseline value at the end of reoxygenation in the amiloride hearts but to only 41+12% in the absence of the drug (p<0.001). At the end of reoxygenation, EDP ( Figure 3B ) falls to 25±6 mm Hg in the amiloride hearts but to only 52±15 mm Hg in its absence (p<0.002). PCr recovers to 99+9% of the baseline value in the presence of amiloride but to only 70±14% in its absence (p<0.001). Recovery of intracellular pH is also markedly affected by the drug. Mean pH in the amiloride hearts shows no further fall during early reoxygenation and recovers to a mean of 7.17. During early reoxygenation, the pH of the control hearts decreases further, to a mean of 6.73 at 15 minutes, before eventually rising to 6.88 at the end of the reoxygenation period (p<0.001). A decrease in intracellular pH during posthypoxic reoxygenation has been observed in myocardial tissue. 45 There is a small but statistically significant difference in ATP, which recovers only a small extent in both groups to a mean of 41% and 53% of baseline values in the amiloridefree and amiloride hearts, respectively (p<0.05). Pi remains significantly elevated (350±285% of initial vs. 83±13%; p<0.05) and the PCr-to-P, ratio is significantly lower (2.7±3.5 vs. 10.8±6.4; p<0.05) in amiloride-free hearts at the end of reoxygenation as compared with amiloride hearts. All values were compared using two-way repeated-measures ANOVA. Cell ionic contents. Cell calcium and sodium contents were measured at the end of the reoxygenation period (six in each group) and in a separate group of nine hearts (five in the presence of amiloride and four in its absence), at the end of hypoxia. These results are compared with those from time-control hearts in the presence (n=6) and absence (n=6) of amiloride in Figure 5 . The results in the time-control hearts in the absence of amiloride are similar to previously published data using this technique.3536 Calcium content is reduced (2.53 ± 0.49 vs. 3.68± 0.58 ,umol/g dry wt; p<0.01) in the presence of 0.1 mM amiloride under normal perfusion conditions. At the end of 40 minutes of hypoxia, there is no difference in cellular calcium between the amiloride and control groups (3.3 ±0.4 vs. 3.6+0.9; p=NS). Cell calcium is higher in each group after 40 minutes of reoxygenation than after hypoxia, but the increase is significantly less marked in the amiloride (5.1±1.3) than in the amiloride-free (10.4±1.8;p<0.001) hearts.
Mean cellular sodium did not differ between amiloride (41.5±36 gmol/g dry wt) and amiloridefree (54.3 ±28.4 ,umol/g dry wt; p=NS) hearts during normal baseline perfusion conditions. Cell sodium was higher at the end of hypoxia (133.8+35.3 and 92.0±16.9) than at baseline and lower at the end of reoxygenation (39.9±19.9 and 69.0±33.1) than at the end of hypoxia in amiloride and amiloride-free hearts, respectively. However, the latter decline was statistically significant (p<0.05) in only the amiloride hearts.
The ratios of wet weight to dry weight as well as ECS measurements are presented in Table 2 . Although the ECS and weight ratios decreased during substrate-free hypoxia, neither the ECS nor the weight ratios differed in the amiloride-free and amiloride hearts under conditions of normal perfusion, hypoxia, or reoxygenation.
Amiloride Effect on Manifestations of Sodium-Mediated Calcium Gain
Normoxic lithium-substituted low sodium perfusion causes exchange of extracellular calcium for intracellular sodium via Na-Ca exchange with a subsequent calcium-mediated transient increase in DP and a later decrease in pH, ATP, and PCr. 35, 36 The effect of amiloride 0.1 mM on DP during low sodium perfusion is illustrated in Figure 6 . There is a rapid initial rise that is followed by a more gradual decline in both the amiloride and amiloride-free hearts. The peak DP, however, is significantly higher in the absence (284±20%) than in the presence (221±25%; p<0.003) of amiloride. 31P-NMR spectra from representative hearts appear in Figure 7 and demonstrate that the fall in PCr, ATP, and pH with low sodium perfusion is more marked in control than in amiloride hearts. The summed magnetic resonance data are presented in Figures 8A-8E and show that there is a more marked fall in PCr (percent of baseline) (68±9 vs. 85±10), ATP (percent of baseline) (84±9 vs. 104±12), and pH (6.8±0.04 vs. 7.01±0.02) at 15 minutes in control versus amiloride hearts. Pi was higher in amiloride-free hearts at 15 minutes compared with amiloride hearts (percent of baseline) (332±105 vs. 201±74), and the PCr-to-Pi ratio trended lower in control hearts, but the difference did not reach statistical significance (1.5 ± 1.0 vs. 3.0±1.6). Two-way repeated-measures ANOVA demonstrated that during the time studied, amiloride and amiloride-free hearts had significantly different metabolic responses to normoxic low sodium perfusion, as indexed by PCr, ATP, Pi, and intracellular pH. Thus, amiloride limits the early rise in DP and the late acidosis and high-energy phosphate depletion associated with low sodium perfusion. These results are consistent with an inhibition by amiloride of sodium-supported calcium gain. Discussion The cardiac effects of amiloride have not been examined previously in the hypoxia-reoxygenation setting in the isolated, intact heart model. Its effects in other preparations have been ascribed to alterations in cation transport. Amiloride decreases sodium content and activity in cultured chick heart cells25'28'30; in sheep heart Purkinje fibers, this effect is associated with an intracellular acidosis of approximately 0.2 pH units under "physiological" conditions. 29 The significance and magnitude of this effect is related to the intracellular and extracellular sodium concentrations as well as the external and internal pH, and it is probably mediated by an inhibition of the sodium-proton exchange system.25,28-31 Amiloride also is reported to inhibit Na-Ca exchange in porcine46 and bovine24 heart plasma membrane vesicles and rat cardiac myocytes26 as well as in noncardiac tissues.27 46 47 Decreased cell sodium and, consequently, sodiummediated calcium entry are probably responsible for the amiloride-induced negative inotropic effects observed in left atrial guinea pig preparations (0.3-1.7 mM)48 and the decrease in cell motion amplitude of chick embryo ventricular cells under normal perfusion conditions and during sodium-free perfusion. 28 Decreased cell sodium may also, in part, explain amiloride's ability to limit digitalis effects.28'32'49 A mild inhibitory effect on Na,K-ATPase has also been reported in guinea pig ventricular muscle at a dose of 0.1 mM; this may be responsible for the transient inotropic effect observed in some settings.50 minutes of hypoxia, and at the end of 40 minutes of reperfusion in amiloride (a) and amiloride-free (E) hearts. Although cellular calcium is lower in the amiloride hearts during the baseline period, there is no difference at the end of hypoxia.
The considerable calcium gain during reoxygenation, however, is significantly less in the presence ofamiloride. Cell sodium is increased during hypoxia compared with baseline and decreases during reoxygenation, although the latter is statistically significant for only the amiloride group.
The results of the present study describe in the whole heart preparation the ionic, metabolic, and functional effects of amiloride under normal and low sodium perfusion conditions and during exposure to hypoxia and reoxygenation. During normal perfusion, amiloride 1.0 mM decreased DP, which fell to 67% of control after 60 minutes of exposure. This negative inotropic effect was associated with a mild intracellular acidosis (cell pH fell from a mean of 7.20 to 7.07) but no change in high-energy phosphate contents and was probably due to inhibition of Na+-H' exchange. During normal perfusion, amiloride 0.1 mM had no effect on DP or EDP, high-energy phosphates, or intracellular pH (see Table 1 ). The effects of amiloride 0.1 mM on the consequences of sodium-mediated calcium gain under normoxic conditions were evaluated during lithiumsubstituted low sodium perfusion. Previously, we have shown that these conditions result in a calciumdependent transient increase in DP and a subsequent fall in high-energy phosphates and intracellular pH. 35 Amiloride 0.1 mM limited these mechanical and metabolic effects of sodium-mediated calcium gain (Figures 6-8 ) and suggest that amiloride inhibits Na-Ca exchange in this intact rat heart model.
The hypoxia-reoxygenation setting is another paradigm in which cell calcium loading, in part sodium mediated, may significantly alter contractile and metabolic function.1,4-6 Amiloride (0.1 mM) resulted in markedly improved contractile and in metabolic function during reoxygenation. This benefit cannot be attributed to a measurable attenuation of the metabolic accompaniments of hypoxia because amiloride did not change the decline in contractile function, high-energy phosphates, or pH during hypoxia. In addition, coronary perfusion and heart rate were controlled for by experimental design. Drug-induced changes in edema did not occur as neither ratios of wet weight to dry weight nor the ECS measurements differed between the amiloride and amiloride-free groups under control, hypoxic, and reoxygenation conditions. Instead, the ability of amiloride to enhance metabolic and contractile recovery is best explained by the ionic data, which indicate a marked decrease in calcium overload during reoxygenation in the amiloride hearts. Improved contractile performance in the amiloride hearts may also be due to the prevention of the transient further acidosis during reoxygenation, which occurred in the amiloride-free but not in the amiloride-treated hearts. Although this pH effect could be due to a smaller rise in cell calcium loading and, therefore, the fall in pH associated with this rise,51,52 it might also be due to an inhibition of sodium efflux-proton influx directed by Na+-H+ exchange during early reoxygenation. This . Representative 31P-nuclear magnetic resonance spectra from amiloride and amiloride-free hearts before and at the end of 20 minutes of normoxic low sodium perfusion. Each spectrum was acquired with 304 pulses over 10 minutes. Note that the increase in inorganic phosphate (Pi) and declines in phosphocreatine (PCr) and pH are more marked in the amiloride-free than in the amiloride hearts. Std, phosphate standard. exchange may be supported by sodium accumulation during hypoxia. In addition to demonstrating amiloride's effect under the described experimental conditions, the results also provide insight into the consequences and mechanisms of cell calcium overload during reoxygenation. Postulated mechanisms for calcium gain during reoxygenation as well as reperfusion include entry via the socalled voltage-dependent "slow" channel, Na-Ca exchange, and nonspecific entry due to disruption of sarcolemmal integrity.",53-55 The calculation of cell calcium by atomic absorption methodology with the use of KCoEDTA as an extracellular marker in the present study excludes the possibility that sarcolemmal disruption sufficient to allow CoEDTA entry could be responsible for the higher cell calcium determinations. Intact sarcolemma during reoxygenation and unimpaired ability to exclude barium at the same time calcium conductance is markedly increased during reperfusion have been described in other similar models.5'54'55 Although we did not examine the effect of known slow channel blockers, previous studies have demonstrated that neither these nor quiescence significantly diminishes calcium gain or improves functional recovery when administered immediately before reperfusion.56 '57 Recently, it has been demonstrated that amiloride blocks the lowthreshold, voltage-gated calcium channel in guinea pig atrial myocytes and noncardiac tissue. 58 The failure of electrical quiescence to diminish reperfusion calcium gain56 suggests, however, that calcium gain during reperfusion, at least, is not likely to occur via this mechanism.
It is probable, therefore, that the marked limitation of calcium gain associated with amiloride is due to an inhibition of sodium-supported calcium gain resulting from lower cell sodium, a direct effect on the exchanger itself, or both. Although cell sodium rose during hypoxia in each group, no increase in measured cellular calcium occurred. This contrasts with the sodium-mediated calcium gain during similar manipulations of the transsarcolemmal sodium gradient in the absence of hypoxia or ischemia (e.g., during low sodium perfusion and after digitalis administration).8"0,12-14 Therefore, marked calcium gain must be inhibited during hypoxia-possibly by the mild acidosis and the lack of high-energy phosphates, which are needed to support mitochondrial calcium uptake.20'22'23'59'60 However, the partial restoration of high-energy phosphates during reoxygenation in the presence of increased cell sodium could support calcium loading via coupled exchange at that time. The improved metabolic and contractile recovery in the presence of amiloride may, therefore, be attributed to an inhibition of sodium-mediated calcium gain during early reoxygenation. During reoxygenation, sodium decreased from the hypoxic level in both the control and amiloride hearts; the reduction reached statistical significance, however, in only the amiloride hearts. This is not direct evidence that Na-Ca exchange is operative. Other cationic exchangers, such as the ATPdependent Na+-K+ exchanger, are activated with reoxygenation and may also contribute to intracellular sodium extrusion. The worsening acidosis, higher Pi, and lower high-energy phosphates in the amiloride-free hearts may have limited sodium extrusion by this mechanism,61 and this may be why the decline in cell sodium in the amiloride-free hearts did not reach statistical significance.
In summary, amiloride 0.1 mM does not alter cellular pH or contractile performance during normal perfusion conditions in the isolated rat heart. Nevertheless, it has significant functional and metabolic effects, consistent with a net reduction in cell calcium loading when the sarcolemma Na+ gradient is altered during normoxic perfusion. Although amiloride does not alter the decline in high-energy phosphates or pH during hypoxia, it decreases calcium overload during reoxygenation; this probably explains its ability to markedly improve contractile and metabolic recovery at that time. Therefore, interventions that alter sodium-mediated calcium gain during reoxygenation may, independent of any metabolic effect during hypoxia, improve recovery during the reoxygenation period. 
